Haemonetics Corp. (NYSE:HAE) inked a deal with Quotient Biodiagnostics Group subsidiary Alba Bioscience Ltd. that gives it exclusive access to Alba’s portfolio of blood-typing reagents.
The Braintree, Mass.-based blood management products maker will use the reagents for the Arryx laser blood typing platform, which CEO Brian Concannon calls the entry point into a billion-dollar market.